Insmed Incorporated
INSM
Hisse Senetlerindeki Sıralama
#1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Hisse Fiyatı
$95.65
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$20.89B
Değişim (1 gün)
-0.65%
Değişim (1 yıl)
-43.04%
Ülke
US
Ticaret Insmed Incorporated (INSM)
Kategori
Healthcare
Insmed Incorporated (INSM) için P/B oranı
October 2026 itibarıyla P/B oranı TTM: 28.06
Insmed Incorporated şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 28.06'dir. 2023 yılının sonunda şirketin P/B oranı -13.11 idi.
Insmed Incorporated için P/B oranı geçmişi 2000 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 28.06 | -29.30% |
| 2024 | 39.69 | -402.68% |
| 2023 | -13.11 | -146.91% |
| 2022 | 27.95 | 275.67% |
| 2021 | 7.44 | -36.83% |
| 2020 | 11.78 | 52.62% |
| 2019 | 7.72 | 59.41% |
| 2018 | 4.84 | -15.80% |
| 2017 | 5.75 | 8.54% |
| 2016 | 5.30 | 55.48% |
| 2015 | 3.41 | -4.67% |
| 2014 | 3.57 | -13.87% |
| 2013 | 4.15 | 182.67% |
| 2012 | 1.47 | 176.73% |
| 2011 | 0.53 | 22.38% |
| 2010 | 0.43 | -45.13% |
| 2009 | 0.79 | -103.91% |
| 2008 | -20.23 | -345.58% |
| 2007 | 8.24 | 36.28% |
| 2006 | 6.04 | -33.73% |
| 2005 | 9.12 | -23.38% |
| 2004 | 11.90 | 195.16% |
| 2003 | 4.03 | 549.88% |
| 2002 | 0.62 | -70.50% |
| 2001 | 2.10 | 220.36% |
| 2000 | 0.66 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| 6.251 | -77.72% |
US
|
|
| 13.2547 | -52.76% |
US
|
|
| 4.208 | -85.00% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.97% |
NL
|
